|
11th Annual Conference Of The British HIV Association [BHIVA]20–23 April 2005, Burlington Hotel·Dublin·Ireland |
[AUTHOR(S):] L Waters, J Stebbing, S Mandalia, AM Young, M Nelson, BG Gazzard, M Bower
Departments of HIV Medicine and Oncology, The Chelsea and Westminster Hospital, London, UK
BHIVA Conf 2005 Apr 20-23;11:O28
AIM: HIV-associated immunosuppression increases the risk of non-Hodgkin’s lymphoma (NHL). The hepatitis C virus (HCV) has been implicated in the development of B cell lymphomas, and HCV is common in HIV-infected individuals, we compared the incidence of systemic NHL during HIV infection compared with HIV and HCV co-infection.
METHODS: Data were extracted from a prospectively collected database for all patients entering our cohort in the HAART era. To compare lymphoma risk in HIV mono-infected and co-infected individuals, person years at risk (PYAR) was estimated from cohort entry to i) end of study period, ii) NHL development, iii) last recorded visit or iv) date of death. Data were analysed using the Genmod with loge link and Poisson error distributions; all P values are two-sided. All NHL cases were biopsy-proven and primary CNS lymphomas were excluded.
RESULTS: Out of 5,832 individuals studied during the era of highly active anti-retroviral therapy (HAART), 102 patients were diagnosed with systemic NHL. The incidence of systemic NHL was 6.9/104 patient years in co-infected individuals compared with 7.1/104 patient years if HIV mono-infected (P=0.9).
CONCLUSIONS: In this immunocompromised patient population, there was no association between HCV infection and an increased risk of lymphoma.
PRESENTING AUTHOR: L Waters
2005-04-20
O28
Copyright © 2005 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD